Literature DB >> 30431113

miRNA‑885‑3p inhibits docetaxel chemoresistance in lung adenocarcinoma by downregulating Aurora A.

Jiongrui Cao1, Jian Geng1, Xiaoyuan Chu1, Rui Wang1, Guichun Huang1, Longbang Chen1.   

Abstract

Aurora A is a member of the mitotic serine/threonine kinase family. It is involved in key processes during mitosis and meiosis, and Aurora A upregulation is implicated in malignant transformation. In the present study, we revealed that Aurora A expression was significantly higher in docetaxel‑resistant lung adenocarcinoma (LAD) cells than in parental cells. Higher levels of Aurora A expression were significantly correlated with higher chemoresistance and proliferation in LAD cells, while silencing Aurora A promoted caspase‑3‑dependent cell apoptosis by downregulating NF‑κB and Bcl‑2 and upregulating Bax expression. In addition, an increased proportion of cells in the G2/M phase and a decreased proportion of cells in the S phase were observed due to the suppression of Aurora A. Furthermore, we identified that microRNA‑885‑3p (miR‑885‑3p) could target Aurora A directly. There was significantly lower miR‑885‑3p expression in docetaxel‑resistant LAD cells than in parental LAD cells. miR‑885‑3p could modulate the docetaxel response, cell proliferation and apoptosis in LAD cells in vitro. Moreover, we found that Aurora A overexpression or miR‑885‑3p inhibition was associated with more aggressive behaviour in LAD cells. Thus, miR‑885‑3p/Aurora A may be involved in the chemoresistance of LAD cells, and assessing miR‑885‑3p/Aurora A expression may be a potential method for indicating chemosensitivity to docetaxel‑based chemotherapy.

Entities:  

Year:  2018        PMID: 30431113     DOI: 10.3892/or.2018.6858

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Plasma Exosomes Transfer miR-885-3p Targeting the AKT/NFκB Signaling Pathway to Improve the Sensitivity of Intravenous Glucocorticoid Therapy Against Graves Ophthalmopathy.

Authors:  Jingxue Sun; Jiaxing Wei; Yaguang Zhang; Jingjing Li; Jian Li; Jiazhuo Yan; Min Guo; Jun Han; Hong Qiao
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 7.561

2.  MicroRNA-885-3p alleviates bronchial epithelial cell injury induced by lipopolysaccharide via toll-like receptor 4.

Authors:  Yahui Shen; Aigui Jiang; Rong Chen; Xiaoyan Gao; Guixian Song; Huiyu Lu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

3.  Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lung cancer.

Authors:  Feiyun Chang; Jiali Li; Quan Sun; Shuqing Wei; Yongming Song
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

4.  Circular RNA_0006014 promotes breast cancer progression through sponging miR-885-3p to regulate NTRK2 and PIK3/AKT pathway.

Authors:  Xiqian Zhou; Wei Jian; Qifeng Luo; Wenfang Zheng; Xiaochong Deng; Xuehui Wang; Oyungerel Borkhuu; Changle Ji; Dengfeng Li; Lin Fang
Journal:  Aging (Albany NY)       Date:  2022-04-05       Impact factor: 5.682

5.  Network Pharmacology and Comparative Transcriptome Reveals Biotargets and Mechanisms of Curcumol Treating Lung Adenocarcinoma Patients With COVID-19.

Authors:  Lu Yang; Hao Xiong; Xin Li; Yu Li; Huanhuan Zhou; Xiao Lin; Ting Fung Chan; Rong Li; Keng Po Lai; Xu Chen
Journal:  Front Nutr       Date:  2022-04-19

6.  circ_0061265 competitively binds to microRNA-885-3p to promote the development of gastric cancer by upregulating AURKA expression.

Authors:  Qian Fei; Yuhe Lin; Mi Zhang; Jinshuai Guo; Yuan Liang
Journal:  Cancer Cell Int       Date:  2022-09-05       Impact factor: 6.429

7.  MiR-579 Inhibits Lung Adenocarcinoma Cell Proliferation and Metastasis via Binding to CRABP2.

Authors:  Qijun Yi; Yu'e Miao; Ying Kong; Yan Xu; Jinghao Zhou; Qi Dong; Haiyan Liu
Journal:  Comput Math Methods Med       Date:  2022-08-04       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.